Artisan Raises $9.4M in Debt Round

Xconomy Boston — 

Artisan Pharma, a Waltham, MA-based developer of a biotech drug for a blood-clotting condition in sepsis patients, has raised $9.4 million of an $11.8 million round of debt financing, the firm reported yesterday in an SEC filing. The filing did not specify the investors in the debt round, which may also include the sale of warrants and options to buy equity in Artisan. Artisan says its lead drug, recombinant thrombomodulin, was licensed from Tokyo-based Asahi Kasei Pharma to develop the treatment in non-Asian markets.

By posting a comment, you agree to our terms and conditions.

Comments are closed.